Cambrex Corporation (CBM)
(Delayed Data from NYSE)
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Insmed (INSM) Wins FDA Nod for Lung Disease Drug Arikayce
by Zacks Equity Research
Insmed's (INSM) lung infection drug Arikayce gains an accelerated approval from the FDA for the treatment of lung disease caused by mycobacterium avium complex (MAC).
AMAG In-Licenses Global Rights to Orphan Drug Candidate
by Zacks Equity Research
AMAG acquires global rights to develop/market DIF from Velo Bio to boost its maternal health portfolio. The candidate is under assessment for treating severe preeclampsia in pregnant women.
Vanda Pharmaceuticals (VNDA) Catches Eye: Stock Jumps 8.7%
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Verastem Out-Licenses China Rights to Cancer Drug Copiktra
by Zacks Equity Research
Verastem (VSTM) out-licenses rights to develop/commercialize its newly approved cancer drug Copiktra to the Chinese entity, CSPC Pharmaceutical.
Arena (ARNA) Posts Favorable Top-Line Data on Pain Candidate
by Zacks Equity Research
Arena (ARNA) releases initial optimistic outcomes from a phase IIa study on its pipeline candidate olorinab for treating abdominal pain associated with Crohn's disease.
Cambrex (CBM): Moving Average Crossover Alert
by Zacks Equity Research
Cambrex Corporation (CBM) is looking like an interesting pick from a technical perspective
CBM vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CBM vs. ILMN: Which Stock Is the Better Value Option?
BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 7.9%
by Zacks Equity Research
BioMarin Pharmaceutical (BMRN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Should Value Investors Pick Cambrex (CBM) Stock?
by Zacks Equity Research
Cambrex (CBM) is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front.
Is Cambrex Corporation (CBM) a Suitable Value Stock?
by Zacks Equity Research
Cambrex Corporation (CBM) appears to be a good choice for value investors right now, given its favorable metrics and estimate revisions.
The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cambrex, Geron, Anavex Life Sciences and Histogenics
Enzo Biochem (ENZ) Looks Good: Stock Jumps 13.3% in Session
by Zacks Equity Research
Enzo Biochem, Inc. (ENZ) shares rose above 13% in the last trading session.
Does Cambrex Offer a Great Value Buying Opportunity Right Now?
by Zacks Equity Research
Value investing is easily one of the most popular ways to find great stocks in any market environment.
Merck KGaA Expands Distribution Deal with Roche (revised)
by Zacks Equity Research
Germany-based Merck KGaA announced that it has expanded the distribution alliance with Roche Holding AG (RHHBY).
Momenta (MNTA) to Receive $50M Under CSL Collaboration
by Zacks Equity Research
Momenta Pharmaceuticals, Inc. (MNTA) entered into an exclusive research collaboration and worldwide license agreement with CSL Limited.
Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group
by Zacks Equity Research
Zacks.com featured highlights: Braskem, Cambrex, Daqo New Energy, State National Companies and International Consolidated Airlines Group
Genocea Stock Up on Positive Genital Herpes Infections Data
by Zacks Equity Research
Genocea Biosciences, Inc. (GNCA) announced encouraging six-month data from a planned interim analysis of its ongoing placebo-controlled phase IIb study on GEN-003 for the treatment of genital herpes infections.
Ultragenyx's (RARE) KRN23 Accepted for Review in the EU
by Zacks Equity Research
Ultragenyx (RARE) announced that EMA has accepted to review its MAA for KRN23 for the treatment of X-linked hypophosphatemia.
Arena, Eisai Modify Marketing & Supply Agreement for Belviq
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) announced that it has amended the marketing and supply agreement with Eisai Co., Ltd. (ESALY) for Belviq.
Spark Therapeutics Gets $15M Milestone Payment from Pfizer
by Zacks Equity Research
Spark Therapeutics (ONCE) received a $15 million milestone payment from partner Pfizer Inc. (PFE) for achieving a pre-specified safety and efficacy profile in the phase I/II study on SPK-9001, which is being evaluated for the treatment of hemophilia B.
Ocular (OCUL) Reports Positive Phase III Data on Eye Drug
by Zacks Equity Research
Shares of Ocular Therapeutix, Inc. (OCUL) were up 3% following the company's announcement of positive results from its third phase III trial on lead pipeline candidate Dextenza 0.4 mg for the treatment of post-surgical ocular inflammation and pain.
Evoke Diabetic Gastroparesis Drug Gimoti Positive in Phase III
by Zacks Equity Research
Pharma, Inc. (EVOK) announced additional data from a phase III trial on Gimoti (nasal delivery), a novel formulation of its marketed drug, metoclopramide, for diabetic gastroparesis in adult women.
Zacks.com featured expert Kevin Matras highlights: Morgan Stanley, Pennymac Mortgage, Cambrex, DTE Energy and Choice Hotels
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Morgan Stanley, Pennymac Mortgage, Cambrex, DTE Energy and Choice Hotels
Top 5 Stocks with Solid Net Profit Margin
by Zacks Equity Research
Net profit margin reflects a company's ability to convert revenues into profit after deducting all operating and non-operating expenses as well as income tax payable.
Allergan (AGN) Liletta sNDA Accepted for Review in the U.S.
by Zacks Equity Research
Allergan plc (AGN) and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed intrauterine system (IUS), Liletta.